Navigation auf zora.uzh.ch

Search ZORA

ZORA (Zurich Open Repository and Archive)

Practical suggestions on intravenous iloprost in Raynaud's phenomenon and digital ulcer secondary to systemic sclerosis: Systematic literature review and expert consensus

Ingegnoli, Francesca; Schioppo, Tommaso; Allanore, Yannick; Caporali, Roberto; Colaci, Michele; Distler, Oliver; Furst, Daniel E; Hunzelmann, Nicolas; Iannone, Florenzo; Khanna, Dinesh; Matucci-Cerinic, Marco (2019). Practical suggestions on intravenous iloprost in Raynaud's phenomenon and digital ulcer secondary to systemic sclerosis: Systematic literature review and expert consensus. Seminars in Arthritis and Rheumatism, 48(4):686-693.

Abstract

BACKGROUND Systemic sclerosis (SSc) is an autoimmune chronic disease characterized by vascular impairment, immune dysfunction and collagen deposition. Raynaud's phenomenon (RP) and digital ulcers (DU) are prominent features of SSc. Intravenous (IV) iloprost (ILO), according to the recently updated EULAR recommendations, is indicated for RP after failure of oral therapy. Moreover, IV ILO could be useful in DU healing. IV ILO is currently available mainly on the European market approved for RP secondary to SSc with 3-5 days infusion cycle. Unfortunately, data published varies regarding regimen (dosage, duration and frequency). Up to now, ILO has been studied in small cohorts of patients and in few randomized controlled trials. METHODS A systematic review of studies on IV ILO in patients with SSc complicated by DU and RP was performed. Insufficient data were available to perform a meta-analysis according to the GRADE system. We performed a three-stage internet-based Delphi consensus exercise. RESULTS Three major indications were identified for IV ILO usage in SSc: RP non-responsive to oral therapy, DU healing, and DU prevention. IV ILO should be administered between 0.5 and 2.0ng/kg/min according to patient tolerability with a frequency depending on the indication. CONCLUSIONS Although these suggestions are supported by this expert group to be used in clinical setting, it will be necessary to formally validate the present suggestions in future clinical trials.

Additional indexing

Item Type:Journal Article, refereed, further contribution
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Rheumatology Clinic and Institute of Physical Medicine
Dewey Decimal Classification:610 Medicine & health
Scopus Subject Areas:Health Sciences > Rheumatology
Health Sciences > Anesthesiology and Pain Medicine
Language:English
Date:1 February 2019
Deposited On:24 May 2018 08:17
Last Modified:19 Oct 2024 01:35
Publisher:Elsevier
ISSN:0049-0172
OA Status:Closed
Publisher DOI:https://doi.org/10.1016/j.semarthrit.2018.03.019
PubMed ID:29706243

Metadata Export

Statistics

Citations

Dimensions.ai Metrics
36 citations in Web of Science®
36 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

0 downloads since deposited on 24 May 2018
0 downloads since 12 months

Authors, Affiliations, Collaborations

Similar Publications